MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
11
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
9.1%
1 terminated/withdrawn out of 11 trials
90.9%
+4.4% vs industry average
27%
3 trials in Phase 3/4
110%
11 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole
Role: collaborator
Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers
Role: collaborator
A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children
Role: collaborator
Study of MAP0010 in Asthmatic Children and Adolescents
Role: collaborator
Safety and Blood Level Study of Unit Dose Budesonide
Role: collaborator
Phase 3 Study of MAP0004 in Adult Migraineurs
Role: collaborator
A Study of 2 Doses of MAP0010 in Adult Asthmatics
Role: collaborator
Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure
Role: collaborator
QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo
Role: collaborator
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
Role: collaborator
A Study of 2 Doses of MAP0010 in Asthmatic Children
Role: collaborator
All 11 trials loaded